Last reviewed · How we verify
NCT07011108: FitML-O
Machine Learning for Estimating Cardiorespiratory Fitness in Patients With Obesity
trial testing No intervention (observational study) in Obesity; Overweight in 1,700 participants. Participants enrolled and being followed up; not accepting new ones.
10 December 2027
Quick facts
| Lead sponsor | Sykehuset i Vestfold HF |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 1,700 |
| Start date | 30 May 2025 |
| Primary completion | 10 December 2027 |
| Estimated completion | 24 December 2027 |
Drugs / interventions tested
- No intervention (observational study) — full drug profile →
Conditions studied
- Obesity; Overweight — all drugs for Obesity; Overweight →
Sponsor
Sykehuset i Vestfold HF — full company profile →
Who can join
Adults 18 to 100, any sex, with Obesity; Overweight. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary aim of this study is to develop an obesity-specific machine learning (ML) model capable of accurately estimating VO2max, a key indicator of cardiovascular fitness.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Machine Learning for Estimating Cardiorespiratory Fitness in Patients With Obesity: Protocol for a Retrospective and Prospective Multicenter Cohort Study.
Berge J, Nunavath V, Asbjørnsen RA, Borgeraas H, et al · · 2026 · PMID 41773679 · DOI 10.2196/85069
Verify or expand the search:
- PubMed search for NCT07011108
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of No intervention (observational study)
Trials testing the same drug.
- NCT07527676 — Hypoglycemia Fear Affect Autonomic Function, Physical Activity, and Exercise Capacity in Type I Diabetes · not yet recruiting
- NCT07527000 — SpO2 Validation Study - All.Health Algo Oximeter Software · not yet recruiting
- NCT07495735 — Intelligence System for Predicting Atezolizumab-Bevacizumab Response and Clinical Outcomes in Unresectable Hepatocellula · not yet recruiting
- NCT07504406 — Assessment of Medication Adherence in Ccu Admitted Patients · not yet recruiting
- NCT07324655 — Association Between Office Ergonomics, Work Organization, and Musculoskeletal Complaints in Medical Secretaries · recruiting
Other Sykehuset i Vestfold HF trials
Trials by the same sponsor.
- NCT06468865 — Glucose Monitoring in Treatment of Postprandial Hypoglycemia After Gastric Bypass Surgery · NA · recruiting
- NCT06045741 — Virtual Reality - A New Vision on Pain · completed
- NCT05858255 — Hjernegym - Effects of Exergaming in Psychosis: a Clinical Intervention Study · NA · recruiting
- NCT04659395 — How to Develop a Training Program for Nurses in Ultrasound Guided Femoral Nerve Block · NA · completed
- NCT03695081 — Patient Pathway Pharmacist - Optimal Drug-related Care · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07011108 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sykehuset i Vestfold HF
- Last refreshed: 8 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07011108.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing